

Robert F Dannals

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5021066/publications.pdf>

Version: 2024-02-01

116
papers

7,960
citations

76196

40
h-index

53109

85
g-index

124
all docs

124
docs citations

124
times ranked

8382
citing authors

#	ARTICLE	IF	CITATIONS
1	11C-Para-aminobenzoic acid PET imaging of <i>S. aureus</i> and MRSA infection in preclinical models and humans. <i>JCI Insight</i> , 2022, 7, .	2.3	11
2	Regional amyloid correlates of cognitive performance in ageing and mild cognitive impairment. <i>Brain Communications</i> , 2022, 4, fca016.	1.5	5
3	PET/CT imaging of CSF1R in a mouse model of tuberculosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4088-4096.	3.3	1
4	18F-labeled radiotracers for in vivo imaging of DREADD with positron emission tomography. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113047.	2.6	7
5	First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3122-3128.	3.3	6
6	Imaging <i>Enterobacteriales</i> infections in patients using pathogen-specific positron emission tomography. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	49
7	Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression. <i>Neuropharmacology</i> , 2021, 194, 108447.	2.0	10
8	Dynamic PET-facilitated modeling and high-dose rifampin regimens for <i>Staphylococcus aureus</i> orthopedic implant-associated infections. <i>Science Translational Medicine</i> , 2021, 13, eabl6851.	5.8	16
9	The Relationship of Varenicline Agonism of $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptors and Nicotine-Induced Dopamine Release in Nicotine-Dependent Humans. <i>Nicotine and Tobacco Research</i> , 2020, 22, 892-899.	1.4	8
10	High Availability of the $\alpha 7$ -Nicotinic Acetylcholine Receptor in Brains of Individuals with Mild Cognitive Impairment: A Pilot Study Using ¹⁸ F-ASEM PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 423-426.	2.8	22
11	Osteopontin/secreted phosphoprotein-1 behaves as a molecular brake regulating the neuroinflammatory response to chronic viral infection. <i>Journal of Neuroinflammation</i> , 2020, 17, 273.	3.1	14
12	¹¹ C-PABA as a PET Radiotracer for Functional Renal Imaging: Preclinical and First-in-Human Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1665-1671.	2.8	11
13	Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. <i>Nature Medicine</i> , 2020, 26, 529-534.	15.2	87
14	PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP. <i>EJNMMI Research</i> , 2020, 10, 67.	1.1	10
15	Radiosynthesis and validation of [¹¹ C]4-aminobenzoic acid ([¹¹ C]PABA), a PET radiotracer for imaging bacterial infections. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 28-33.	0.5	6
16	Radiosynthesis and validation of [5-cyano- <i>N</i> -(4-(¹¹ C)methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl]furan-2-carboxamide ([¹¹ C]CPPC), a PET radiotracer for imaging CSF1R, a microglia-specific marker. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 903-908.	0.5	10
17	Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 235-241.	1.1	12
18	PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1686-1691.	3.3	140

#	ARTICLE	IF	CITATIONS
19	A side-by-side evaluation of [¹⁸ F]FDOPA enantiomers for non-invasive detection of neuroendocrine tumors by positron emission tomography. <i>Oncotarget</i> , 2019, 10, 5731-5744.	0.8	3
20	Synthesis and Evaluation of a New ¹⁸ F-Labeled Radiotracer for Studying the GABAB Receptor in the Mouse Brain. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1453-1461.	1.7	7
21	¹⁸ F-XTRA PET for Enhanced Imaging of the Extrathalamic $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptor. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1603-1608.	2.8	15
22	An optimized radiosynthesis of [¹⁸ F]FNDP, a positron emission tomography radiotracer for imaging soluble epoxide hydrolase (sEH). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 567-572.	0.5	8
23	Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 320-332.	2.3	24
24	Characterization of 3 Novel Tau Radiopharmaceuticals, ¹¹ C-RO-963, ¹¹ C-RO-643, and ¹⁸ F-RO-948, in Healthy Controls and in Alzheimer Subjects. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1869-1876.	2.8	81
25	Preclinical Evaluation of ¹⁸ F-RO6958948, ¹¹ C-RO6931643, and ¹¹ C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2018, 59, 675-681.	2.8	71
26	The distribution of the $\alpha 7$ nicotinic acetylcholine receptor in healthy aging: An in vivo positron emission tomography study with [¹⁸ F]ASEM. <i>NeuroImage</i> , 2018, 165, 118-124.	2.1	27
27	Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [¹¹ C]DPA-713 PET. <i>Journal of Neuroinflammation</i> , 2018, 15, 346.	3.1	46
28	Noninvasive ¹¹ C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	73
29	Peptide-Based ⁶⁸ Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer. <i>Molecular Pharmaceutics</i> , 2018, 15, 3946-3952.	2.3	102
30	Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players. <i>JAMA Neurology</i> , 2017, 74, 67.	4.5	134
31	Development of a radioligand for imaging V _{1a} vasopressin receptors with PET. <i>European Journal of Medicinal Chemistry</i> , 2017, 139, 644-656.	2.6	8
32	Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. <i>Science</i> , 2017, 357, 503-507.	6.0	813
33	Imaging $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptors (nAChRs) in Baboons with [¹⁸ F]XTRA, a Radioligand with Improved Specific Binding in Extra-Thalamic Regions. <i>Molecular Imaging and Biology</i> , 2017, 19, 280-288.	1.3	11
34	Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [¹¹ C]DPA-713 positron emission tomography. <i>Lupus</i> , 2017, 26, 170-178.	0.8	25
35	PSMA-Based [¹⁸ F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 411-419.	1.3	202
36	¹⁸ F-FNDP for PET Imaging of Soluble Epoxide Hydrolase. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1817-1822.	2.8	19

#	ARTICLE	IF	CITATIONS
37	An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [¹⁸ F]DCFPyL. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 439-450.	0.5	59
38	Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7840-7855.	2.9	47
39	Synthesis and quality control of [¹⁸ F]T807 for tau PET imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 411-415.	0.5	23
40	PET-measured longitudinal flow gradient correlates with invasive fractional flow reserve in CAD patients. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 18, jew116.	0.5	18
41	Comparison of Prostate-Specific Membrane Antigen-Based ¹⁸ F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 46-53.	2.8	111
42	P4185: First in-human PET study of 3 novel tau radiopharmaceuticals: [¹¹ C]RO6924963, [¹¹ C]RO6931643, and [¹⁸ F]RO6958948. <i>Alzheimer's and Dementia</i> , 2015, 11, P850.	0.4	12
43	Bengt Långström: personal recollections of the gentle giant of short-lived radiotracers. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 49-50.	0.5	0
44	Cannabinoid CB2 Receptors in a Mouse Model of A β 2 Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation. <i>PLoS ONE</i> , 2015, 10, e0129618.	1.1	83
45	Multiparametric Molecular Imaging Provides Mechanistic Insights into Sympathetic Innervation Impairment in the Viable Infarct Border Zone. <i>Journal of Nuclear Medicine</i> , 2015, 56, 457-463.	2.8	37
46	[¹²⁵ I]Iodo-ASEM, a specific in vivo radioligand for α 7-nAChR. <i>Nuclear Medicine and Biology</i> , 2015, 42, 488-493.	0.3	8
47	Mechanistic Insights into Sympathetic Neuronal Regeneration. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, e003507.	1.3	23
48	¹⁸ F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1003-1010.	2.8	180
49	Determination of [¹¹ C]Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice by Using Dynamic Positron Emission Tomography Bioimaging. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5768-5774.	1.4	47
50	Brown Adipose Tissue Response Dynamics: In Vivo Insights with the Voltage Sensor 18F-Fluorobenzyl Triphenyl Phosphonium. <i>PLoS ONE</i> , 2015, 10, e0129627.	1.1	12
51	Dose-dependent, saturable occupancy of the metabotropic glutamate subtype 5 receptor by fenobam as measured with [¹¹ C]ABP688 PET imaging. <i>Synapse</i> , 2014, 68, 565-573.	0.6	21
52	Positron emission tomography radioligands for the opioid system. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 187-195.	0.5	18
53	Characterization of [¹¹ C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. <i>NeuroImage</i> , 2013, 75, 282-290.	2.1	26
54	Pre-clinical characterization of [¹¹ C]RO5013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography. <i>NeuroImage</i> , 2013, 75, 291-300.	2.1	16

#	ARTICLE	IF	CITATIONS
55	Dissociative Changes in the B ₂ and K _D of Dopamine D ₂ /D ₃ Receptors with Aging Observed in Functional Subdivisions of the Striatum: A Revisit with an Improved Data Analysis Method. <i>Journal of Nuclear Medicine</i> , 2012, 53, 805-812.	2.8	17
56	Radiosynthesis of [¹¹ C]methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methoxyphenyl)-5-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-3-carboxamide ([¹¹ C]RO5013853), a novel PET tracer for the glycine transporter type I (GlyT1). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2011, 54, 702-707.	0.5	5
57	Radiosynthesis of the α 2 nicotinic acetylcholine receptor ligand: 5-((1-[¹¹ C]-methyl-2-(S)-pyrrolidinyl)methoxy)-2-chloro-3-((E)-2-(2-fluoropyridin-4-yl)vinyl)pyridine. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 459-462.	0.5	0
58	Synthesis of a mGluR5 antagonist using [¹¹ C]copper(I) cyanide. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 829-834.	0.5	22
59	Synthesis of [¹¹ C]gefitinib for imaging epidermal growth factor receptor tyrosine kinase with positron emission tomography. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 883-888.	0.5	19
60	Synthesis of 1-(2,4-dichlorophenyl)-4-cyano-5-(4-[¹¹ C]methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([¹¹ C]JHU75528) and 1-(2-bromophenyl)-4-cyano-5-(4-[¹¹ C]methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([¹¹ C]JHU75575) as potential radioligands for PET imaging of cerebral cannabinoid receptor. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 1021-1036.	0.5	32
61	Characterization of dose dependent norepinephrine transporter blockade by atomoxetine in human brain using ¹¹ C MeNER PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S599-S599.	2.4	2
62	Radiosynthesis of 3-[¹⁸ F]fluoropropyl and 4-[¹⁸ F]fluorobenzyl triarylphosphonium ions. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2004, 47, 469-476.	0.5	52
63	Neural basis of alertness and cognitive performance impairments during sleepiness II. Effects of 48 and 72 h of sleep deprivation on waking human regional brain activity. <i>Thalamus & Related Systems</i> , 2003, 2, 199.	0.5	91
64	¹¹ C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase). <i>Molecular Imaging</i> , 2002, 1, 153535002002021.	0.7	27
65	[¹¹ C]-GR89696, a potent kappa opiate receptor radioligand; in vivo binding of the R and S enantiomers. <i>Nuclear Medicine and Biology</i> , 2002, 29, 47-53.	0.3	34
66	Radiosynthesis of [¹¹ C]paclitaxel. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2002, 45, 471-477.	0.5	17
67	Use of Positron Emission Tomography to Study AT1 Receptor Regulation In Vivo. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1350-1358.	3.0	37
68	Synthesis and initial in vitro characterization of 6-[¹⁸ F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine, a high-affinity radioligand for central nicotinic acetylcholine receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2000, 43, 413-423.	0.5	16
69	Neural basis of alertness and cognitive performance impairments during sleepiness. I. Effects of 24 h of sleep deprivation on waking human regional brain activity. <i>Journal of Sleep Research</i> , 2000, 9, 335-352.	1.7	914
70	Column-switching HPLC for the analysis of plasma in PET imaging studies. <i>Nuclear Medicine and Biology</i> , 2000, 27, 627-630.	0.3	191
71	Effect of tracer metabolism on PET measurement of [¹¹ C]pyrilamine binding to histamine H1 receptors. <i>Annals of Nuclear Medicine</i> , 1999, 13, 101-107.	1.2	9
72	Doses of GBR12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by [¹¹ C] WIN35,428 PET scans. , 1999, 32, 44-50.		50

#	ARTICLE	IF	CITATIONS
73	GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [¹¹ C]raclopride continuous infusion PET scans. <i>Synapse</i> , 1999, 33, 268-273.	0.6	50
74	Synthesis of N1-([¹⁸ F]fluoroethyl)naltrindole ([¹⁸ F]FETNTI): a radioligand for positron emission tomographic studies of delta opioid receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1999, 42, 43-54.	0.5	11
75	Synthesis of [¹⁸ F] SR144385: a selective radioligand for positron emission tomographic studies of brain cannabinoid receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1999, 42, 589-596.	0.5	16
76	[¹¹ C]-methyl 4-[(3,4-dichlorophenyl)acetyl]-3-[(1-pyrrolidinyl)methyl]-1-piperazinecarboxylate ([¹¹ C]GR89696): synthesis and in vivo binding to kappa opiate receptors. <i>Nuclear Medicine and Biology</i> , 1999, 26, 737-741.	0.3	28
77	In vivo detection of short- and long-term MDMA neurotoxicity? a positron emission tomography study in the living baboon brain. <i>Synapse</i> , 1998, 29, 183-192.	0.6	141
78	Nicotine induced up-regulation of nicotinic receptors in CD-1 mice demonstrated with an in vivo radiotracer: Gender differences. <i>Synapse</i> , 1998, 30, 116-118.	0.6	40
79	Cerebral Glucose Utilization Is Reduced in Second Test Session. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1997, 17, 704-712.	2.4	43
80	Imaging of μ - and δ -opioid receptors in temporal lobe epilepsy by positron emission tomography. <i>Annals of Neurology</i> , 1997, 41, 358-367.	2.8	107
81	Synthesis of a radioiodinated analog of epibatidine: (A \pm)-exo-2-(2-iodo-5-pyridyl)-7-azabicyclo[2.2.1]heptane for in vitro and in vivo studies of nicotinic acetylcholine receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1997, 39, 39-48.	0.5	21
82	Synthesis of 3-[(1-[¹¹ C]methyl-2(S)-pyrrolidinyl) methoxy]pyridine and 3-[(1-[¹¹ C]methyl-2(R)-pyrrolidinyl) methoxy]pyridine: Radioligands for in vivo studies of neuronal nicotinic acetylcholine receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1997, 39, 425-431.	0.5	10
83	[¹²⁵ I]/[¹²³ I]IPH: A radioiodinated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors. , 1997, 26, 392-399.		52
84	External monitoring of cerebral nicotinic acetylcholine receptors in living mice. <i>Synapse</i> , 1997, 27, 378-380.	0.6	4
85	Synthesis of 3-[(1-[¹¹ C]methyl-2(S)-pyrrolidinyl) methoxy]pyridine and 3-[(1-[¹¹ C]methyl-2(R)-pyrrolidinyl) methoxy]pyridine: Radioligands for in vivo studies of neuronal nicotinic acetylcholine receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1997, 39, 425-431.	0.5	2
86	Assessing neuroreceptor occupancy by continuous infusion of carbon-11 labeled radioligands. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 141-144.	2.2	2
87	Synthesis of a radiotracer for studying nicotinic acetylcholine receptors: (+/â ⁻)-exo-2-(2-[¹⁸ F]fluoro-5-pyridyl)-7-azabicyclo[2.2.1]heptane. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1996, 38, 355-365.	0.5	67
88	Imaging of δ opioid receptors in human brain by N1 δ - ([¹¹ C]methyl)naltrindole and PET. , 1996, 24, 19-28.		69
89	Increased mu opioid receptor binding detected by PET in cocaine-â€“dependent men is associated with cocaine craving. <i>Nature Medicine</i> , 1996, 2, 1225-1229.	15.2	250
90	Synthesis of N1-([¹¹ C]methyl)naltrindole ([¹¹ C]MeNTI): A radioligand for positron emission tomographic studies of delta opioid receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1995, 36, 137-145.	0.5	21

#	ARTICLE	IF	CITATIONS
91	Synthesis of carbon-11 labeled methylcarbamates from [11C]-methylchloroformate. Journal of Labelled Compounds and Radiopharmaceuticals, 1995, 36, 365-371.	0.5	8
92	Development of imaging agents for the dopamine transporter. Medicinal Research Reviews, 1995, 15, 419-444.	5.0	33
93	Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652. Synapse, 1995, 20, 37-43.	0.6	161
94	Cerebral Glucose Utilization in Polysubstance Abuse. Neuropsychopharmacology, 1995, 13, 21-31.	2.8	48
95	Cerebral Glucose Utilization in Polysubstance Abuse. Neuropsychopharmacology, 1995, 13, 21-31.	2.8	10
96	Buprenorphine Reduces Cerebral Glucose Metabolism in Polydrug Abusers. Neuropsychopharmacology, 1994, 10, 157-170.	2.8	25
97	Decreased hippocampal muscarinic cholinergic receptor binding measured by 123I-iododexetimide and single-photon emission computed tomography in epilepsy. Annals of Neurology, 1993, 34, 235-238.	2.8	35
98	Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Annals of Neurology, 1993, 34, 423-431.	2.8	321
99	Noncompartmental and compartmental modeling of the kinetics of carbon-11 labeled pyrilamine in the human brain. Synapse, 1993, 15, 263-275.	0.6	17
100	In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine-123 labeled RTI-55. Synapse, 1992, 10, 169-172.	0.6	85
101	[123/125I]RTI-55, an in vivo label for the serotonin transporter. Synapse, 1992, 11, 134-139.	0.6	70
102	In vivo studies of [125I]iodobenzamide and [11C]iodobenzamide: A ligand suitable for positron emission tomography and single photon emission tomography imaging of cerebral D2 dopamine receptors. Synapse, 1992, 12, 236-241.	0.6	6
103	Effects of Vasopressin on Blood-Brain Transfer of Methionine in Dogs. Journal of Neurochemistry, 1992, 59, 1421-1429.	2.1	11
104	Imaging Muscarinic Cholinergic Receptors in Human Brain in vivo with SPECT, [123I]4-Iododexetimide, and [123I]4-Iodolevetimide. Journal of Cerebral Blood Flow and Metabolism, 1992, 12, 562-570.	2.4	60
105	Synthesis of a Radiotracer for Studying κ -Subtype Opiate Receptors: N-[11C-methyl]-N-(trans-2-pyrrolidinyl-cyclohexyl)-3,4-dichlorophenylacetamide ([11C](\pm)-U-50488H). Journal of Labelled Compounds and Radiopharmaceuticals, 1992, 31, 81-89.	0.5	12
106	Quantification of Human Opiate Receptor Concentration and Affinity Using High and Low Specific Activity [¹¹ C]Diprenorphine and Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1991, 11, 204-219.	2.4	94
107	Quantification of μ and non- μ opiate receptors in temporal lobe epilepsy using positron emission tomography. Annals of Neurology, 1991, 30, 3-11.	2.8	189
108	Mania after brain injury: Neuroradiological and metabolic findings. Annals of Neurology, 1990, 27, 652-659.	2.8	238

#	ARTICLE	IF	CITATIONS
109	Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. <i>Annals of Neurology</i> , 1990, 28, 57-64.	2.8	400
110	Facile synthesis of [¹¹ C]buprenorphine for positron emission tomographic studies of opioid receptors. <i>International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes</i> , 1990, 41, 745-752.	0.5	19
111	Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy. <i>Annals of Neurology</i> , 1988, 23, 231-237.	2.8	253
112	Localization of serotonin 5-HT ₂ receptors in living human brain by positron emission tomography using N1-([¹¹ C]-methyl)-2-BR-LSD. <i>Synapse</i> , 1987, 1, 393-398.	0.6	94
113	Synthesis of carbon-11 labeled diprenorphine: A radioligand for positron emission tomographic studies of opiate receptors. <i>Tetrahedron Letters</i> , 1987, 28, 4015-4018.	0.7	38
114	Imaging Opiate Receptors in the Human Brain by Positron Tomography. <i>Journal of Computer Assisted Tomography</i> , 1985, 9, 231-236.	0.5	237
115	Radiosynthesis of an opiate receptor binding radiotracer: [¹¹ C]carfentanil. <i>The International Journal of Applied Radiation and Isotopes</i> , 1985, 36, 303-306.	0.7	136
116	In vivo studies of opiate receptors. <i>Annals of Neurology</i> , 1984, 15, 85-92.	2.8	37